Syros Pharmaceuticals, Inc.
SYRS · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $221 | $45 | $204 | $500 |
| - Cash | $140 | $167 | $92 | $174 |
| + Debt | $62 | $64 | $65 | $66 |
| Enterprise Value | $143 | -$59 | $177 | $392 |
| Revenue | $10 | $15 | $23 | $15 |
| % Growth | -33.2% | -36.6% | 55.6% | – |
| Gross Profit | $8 | $12 | $23 | $15 |
| % Margin | 77.3% | 80.1% | 100% | 100% |
| EBITDA | -$157 | -$88 | -$80 | -$79 |
| % Margin | -1,582.1% | -588.4% | -339% | -524.8% |
| Net Income | -$165 | -$95 | -$87 | -$84 |
| % Margin | -1,656.3% | -636.1% | -368.5% | -556.8% |
| EPS Diluted | -5.81 | -7.49 | -13.84 | -18.25 |
| % Growth | 22.4% | 45.9% | 24.2% | – |
| Operating Cash Flow | -$110 | -$123 | -$100 | -$57 |
| Capital Expenditures | -$0 | -$1 | -$1 | -$3 |
| Free Cash Flow | -$110 | -$124 | -$101 | -$61 |